Cerebral Aneurysm, Inflammation, Intracranial Aneurysm
Conditions
Keywords
intracranial aneurysm, PET, inflammation, positron emission tomography, rupture risk
Brief summary
The main purpose of this study is to determine if PET-imaging can be used to evaluate inflammation level of intracranial aneurysms, thus helping to evaluate the rupture risk of intracranial aneurysm.
Detailed description
Study subjects are patients who are diagnosed with an unruptured saccular intracranial aneurysm and planned for elective surgical treatment of intracranial aneurysms. Prior the planned surgery, all study subjects will undergo PET-imaging of the brain with 18F-FDG- and 68Ga-DOTANOC-tracers targeting glucose metabolism and somatostatin receptors in inflammatory cells. After PET-imaging, samples for histopathological examination from the intracranial aneurysm sac will be collected during the surgery from every study subject. Blood samples are collected prior to aneurysm operation from the routine pre-operative laboratory tests. Cerebrospinal fluid samples are collected during the surgical procedure from the surgical site. From blood samples we will evaluate expression of 20 different circulating microRNAs (miRNA) and the level of tumor necrosis factor-1, interleukin 1 beta, vascular endothelial growth factor, and evaluate correlations between miRNA expression and SUVmax in PET-imaging and miRNA and aneurysm histological findings. Correlation between inflammatory findings in histological studies and PET-imaging will be evaluated (correlation of SUVmax to aneurysm histological findings).
Interventions
RADIATIONPET imaging, 18F-FDG
PET-MRI with 18F-FDG
RADIATIONPET imaging, 68Ga-DOTANOC
PET-CT with 68Ga-DOTANOC
Sponsors
University of Turku
Turku University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Fusiform intracranial aneurysms * Following medications: Asetylsalisylic acid or non-steroidal anti-inflammatory drugs. * Patients who have contraindication for magnetic resonance imaging (Pace Makers, foreign ferromagnetic bodies or implants) * Patients who are allergic to contrast agents. * Pregnancy * Underage persons * Patients on somatostatin analogue medication or with known neuroendocrine tumor
Exclusion criteria
* Patients who are diagnosed with unruptured intracranial aneurysm with MRI/MRA or DSA * Patients who are planned to undergo surgical treatment (ligation) of the intracranial aneurysm * Age ≥18 and \<75 years. * Saccular intracranial aneurysm with maximum diameter ≥ 3 mm.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PET-imaging of unruptured intracranial aneurysms | 1 month | Uptake of 18F-FDG or 68Ga-DOTANOC in intracranial arterial aneurysms as compared to contra-lateral normal vessel as SUVmax or TBR. Correlation of uptake of 18F-FDG or 68Ga-DOTANOC (SUVmax or TBR) to aneurysm histological findings (CD45, CD3, CD5, CD20, CD138 and CD68, SSTR2, SSTR3 and SSTR5) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Risk factors for intracranial aneurysm inflammation | 1 month | Uptake of 18F-FDG or 68Ga-DOTANOC and histological findings correlation to aneurysm size and shape, smoking, hypertension, location of aneurysm. |
Countries
Finland
Contacts
Primary ContactDan Laukka, MD
Outcome results
None listed